1. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology. 2008; 115:1079–1082.e5. PMID:
17976727.
2. Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010; 298:158–162. PMID:
20850793.
Article
3. Hickman SJ, Dalton CM, Miller DH, Plant GT. Management of acute optic neuritis. Lancet. 2002; 360:1953–1962. PMID:
12493277.
Article
4. Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992; 326:581–588. PMID:
1734247.
5. Abou Zeid N, Bhatti MT. Acute inflammatory demyelinating optic neuritis: evidence-based visual and neurological considerations. Neurologist. 2008; 14:207–223. PMID:
18617847.
6. Benoilid A, Tilikete C, Collongues N, Arndt C, Vighetto A, Vignal C, et al. Relapsing optic neuritis: a multicentre study of 62 patients. Mult Scler. 2014; 20:848–853. PMID:
24177207.
Article
7. Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain. 2003; 126:276–284. PMID:
12538397.
Article
8. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008; 70:2197–2200. PMID:
18434643.
Article
9. de Seze J, Arndt C, Jeanjean L, Zephir H, Blanc F, Labauge P, et al. Relapsing inflammatory optic neuritis: is it neuromyelitis optica? Neurology. 2008; 70:2075–2076. PMID:
18505981.
10. Marignier R, De Sèze J, Vukusic S, Durand-Dubief F, Zéphir H, Vermersch P, et al. NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler. 2008; 14:440–445. PMID:
18208892.
Article
11. Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry. 2010; 81:109–111. PMID:
20019228.
Article
12. Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol. 2014; 261:17–26. PMID:
23700317.
Article
13. Collongues N, Marignier R, Zéphir H, Blanc F, Vukusic S, Outteryck O, et al. High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. Mult Scler. 2011; 17:720–724. PMID:
21239412.
Article
14. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69:292–302. PMID:
21387374.
Article
15. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85:177–189. PMID:
26092914.
Article
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33:1444–1452. PMID:
6685237.
Article
17. Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. 2008; 126:12–16. PMID:
18195212.
Article
18. Swanton JK, Fernando KT, Dalton CM, Miszkiel KA, Altmann DR, Plant GT, et al. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Mult Scler. 2010; 16:156–165. PMID:
20086028.
Article
19. Biotti D, Bonneville F, Tournaire E, Ayrignac X, Dallière CC, Mahieu L, et al. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. J Neurol. 2017; 264:2173–2175. PMID:
28914353.
Article
20. Cobo-Calvo Á, Ruiz A, D'Indy H, Poulat AL, Carneiro M, Philippe N, et al. MOG antibody-related disorders: common features and uncommon presentations. J Neurol. 2017; 264:1945–1955. PMID:
28770374.
Article
21. Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017; 89:900–908. PMID:
28768844.
Article